Study compares the economics of equine ET and ICSI: full analysis

A new study in the Journal of Equine Veterinary Science takes on a question that comes up routinely in sport horse and high-value breeding practice: how the cost of conventional embryo transfer compares with intracytoplasmic sperm injection. The paper, from Edward L. Squires and R. Ferris, is notable because it focuses on real-world cost data from clinics and breeding farms performing these procedures, rather than discussing technical pros and cons in the abstract. That makes it especially relevant for veterinarians advising clients on reproductive strategy, budgeting, and referral decisions.

The timing fits a broader shift in equine reproduction. Conventional ET has been commercially established for decades, and review literature describes it as a mature technology with relatively stable procedures and pricing. By contrast, ICSI has moved from a specialized rescue tool to a mainstream option in many infertility cases, particularly when clinicians are dealing with older mares, poor embryo recovery, limited semen availability, imported semen, or stallion subfertility. One review in Journal of Equine Veterinary Science says ICSI has become the favored treatment for mare and stallion infertility, while noting that ET still remains a cornerstone technology with longstanding commercial use. (sciencedirect.com)

That background matters because the two approaches solve different clinical problems. ET depends on recovering an embryo from the donor mare after breeding, then transferring it to a synchronized recipient. ICSI, by contrast, collects oocytes directly from the mare and fertilizes them in the lab, which can bypass some uterine or oviductal barriers and reduce sperm requirements. Squires has previously written that ET was initially embraced in part to help older mares with reproductive problems, but poor embryo recovery in some mares drove interest in direct oocyte collection and ICSI. More recent commentary suggests OPU-ICSI can now be more efficient than ET under optimal conditions, though that does not mean it will be the best economic choice in every case. (sciencedirect.com)

The cost question is complicated by what is, and is not, included in a quoted price. ET often looks simpler on paper, but maintaining or accessing recipient mares is a major cost center. The 2020 JEVS review specifically notes that the major cost of an ET program is the purchase and maintenance of a recipient herd. ICSI pricing, meanwhile, is typically unbundled across multiple steps: ovum pick-up, laboratory fees, embryo development, vitrification, storage, shipment, and transfer into either a client-supplied or clinic-supplied recipient. A current U.S. commercial price list from Equine IVF, for example, lists aspiration-related fees plus an $850 embryo development fee and $350 vitrification fee per ICSI embryo, while Avantea lists separate charges for embryo production, transfer, recipient monitoring, and recipient lease options, and offers lower per-embryo pricing when multiple embryos are produced in one session. (sciencedirect.com)

Those commercial examples don’t replace the study’s clinic-level data, but they do reinforce the paper’s premise: “cost” can mean very different things depending on whether a practice is measuring per procedure, per embryo, per transfer, or per pregnancy. They also highlight why direct comparisons are hard without standard definitions. An ET cycle may require repeated flushing attempts and recipient management before success, while one ICSI session may yield no embryo, one embryo, or several. Avantea’s public pricing explicitly acknowledges that biological variability can strongly influence OPU-ICSI outcomes and has built discount policies around that uncertainty. (avantea.it)

On the outcomes side, the current literature helps frame why some clients may still accept higher upfront ICSI costs. Reviews and clinical studies report that ICSI-derived blastocysts can achieve pregnancy rates after transfer similar to fresh embryos collected from donor mares, and established clinical programs have reported post-transfer foaling rates above 50%. That makes ICSI more than a niche salvage procedure, especially in cases where conventional ET is unlikely to perform well because the embryo may never be recovered from the donor mare in the first place. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the practical takeaway is that reproductive counseling is moving toward a case-based economic discussion, not a simple ET-versus-ICSI hierarchy. ET may remain the more straightforward choice for fertile mares with predictable embryo recovery and access to recipient mares. But for older mares, mares with reproductive tract pathology, or matings involving scarce semen, ICSI may offer a better chance of generating a transferable embryo, even if the invoice is more complex and the upfront cost is higher. The real decision point is often cost per successful pregnancy, not cost per procedure. That’s where studies like this can help practices set expectations more clearly with pet parents and breeders, and help referring veterinarians explain why a more expensive-looking option may still be the more rational one in selected cases. (sciencedirect.com)

What to watch: The next step for the field is better apples-to-apples reporting, especially cost per usable embryo, pregnancy, and live foal across mare age groups and infertility categories, as ICSI continues to expand and newer IVF approaches begin to emerge in horses. (pubmed.ncbi.nlm.nih.gov)